Other Viruses Citation List: April 26 - May 9, 2013
Epstein-Barr Virus
1. Bortezomib and SAHA Synergistically Induce ROS-Driven Caspase-dependent Apoptosis of Nasopharyngeal Carcinoma and Block Replication of Epstein-Barr Virus. Hui, K.F., B.H. Lam, D.N. Ho, S.W. Tsao, and A.K. Chiang. Molecular Cancer Therapeutics, 2013. [Epub ahead of print]; PMID[23475956].
[PubMed] OV_0426-050913.
2. Sulfated Small Molecules Targeting EBV in Burkitt Lymphoma: From in Silico Screening to the Evidence of in Vitro Effect on Viral Episomal DNA. Lima, R.T., H. Seca, A. Palmeira, M.X. Fernandes, F. Castro, M. Correia-da-Silva, M.S. Nascimento, E. Sousa, M. Pinto, and M.H. Vasconcelos. Chemical Biology & Drug Design, 2013. 81(5): p. 631-644; PMID[23350710].
[PubMed] OV_0426-050913.
3. Maribavir Inhibits Epstein-Barr Virus Transcription through the EBV Protein Kinase. Whitehurst, C.B., M.K. Sanders, M. Law, F.Z. Wang, J. Xiong, D.P. Dittmer, and J.S. Pagano. Journal of Virology, 2013. 87(9): p. 5311-5315; PMID[23449792].
[PubMed] OV_0426-050913.
Hepatitis B Virus
4. The Entry Inhibitor Myrcludex-B Efficiently Blocks Intrahepatic Virus Spreading in Humanized Mice Previously Infected with Hepatitis B Virus. Volz, T., L. Allweiss, M.B. MB, M. Warlich, A.W. Lohse, J.M. Pollok, A. Alexandrov, S. Urban, J. Petersen, M. Lutgehetmann, and M. Dandri. Journal of Hepatology, 2013. 58(5): p. 861-867; PMID[23246506].
[PubMed] OV_0426-050913.
Hepatitis C Virus
5. Evaluation of anti-HCV Activity and SAR Study of (+)-Lycoricidine through Targeting of Host Heat-stress Cognate 70 (Hsc70). Chen, D.Z., J.D. Jiang, K.Q. Zhang, H.P. He, Y.T. Di, Y. Zhang, J.Y. Cai, L. Wang, S.L. Li, P. Yi, Z.G. Peng, and X.J. Hao. Bioorganic & Medicinal Chemistry Letters, 2013. 23(9): p. 2679-2682; PMID[23511018].
[PubMed] OV_0426-050913.
6. Resistance Profiling of Hepatitis C Virus Protease Inhibitors Using Full-length NS3. Dahl, G., A. Sandstrom, E. Akerblom, and U.H. Danielson. Antiviral Therapy, 2007. 12(5): p. 733-740; PMID[17713156].
[PubMed] OV_0426-050913.
7. Identification of PTC725: An Orally Bioavailable Small Molecule That Selectively Targets the Hepatitis C Virus NS4B Protein. Gu, Z., J.D. Graci, F.C. Lahser, J. Breslin, S.P. Jung, J.H. Crona, P. McMonagle, E. Xia, S. Liu, G. Karp, J. Zhu, S. Huang, A. Nomeir, M. Weetall, N.G. Almstead, S.W. Peltz, X. Tong, R. Ralston, and J.M. Colacino. Antimicrobial Agents and Chemotherapy, 2013. [Epub ahead of print]; PMID[23629699].
[PubMed] OV_0426-050913.
8. Synthesis and Cytostatic and Antiviral Activities of 2'-Deoxy-2',2'-difluororibo- and 2'-Deoxy-2'-fluororibonucleosides Derived from 7-(Het)aryl-7-deazaadenines. Perlikova, P., L. Eberlin, P. Menova, V. Raindlova, L. Slavetinska, E. Tloustova, G. Bahador, Y.J. Lee, and M. Hocek. ChemMedChem, 2013. 8(5): p. 832-846; PMID[23559483].
[PubMed] OV_0426-050913.
9. Discovery of a Novel Series of Non-nucleoside Thumb Pocket 2 HCV NS5B Polymerase Inhibitors. Stammers, T.A., R. Coulombe, J. Rancourt, B. Thavonekham, G. Fazal, S. Goulet, A. Jakalian, D. Wernic, Y. Tsantrizos, M.A. Poupart, M. Bos, G. McKercher, L. Thauvette, G. Kukolj, and P.L. Beaulieu. Bioorganic & Medicinal Chemistry Letters, 2013. 23(9): p. 2585-2589; PMID[23545108].
[PubMed] OV_0426-050913.
10. ACH-806, an NS4A Antagonist, Inhibits Hepatitis C Virus Replication through Altering the Composition of Viral Replication Complexes. Yang, W., Y. Sun, X. Hou, Y. Zhao, J. Fabrycki, D. Chen, X. Wang, A. Agarwal, A. Phadke, M. Deshpande, and M. Huang. Antimicrobial Agents and Chemotherapy, 2013. [Epub ahead of print]; PMID[23629709].
[PubMed] OV_0426-050913.
Herpes Simplex Virus 2
11. Antiviral Activity of Trappin-2 and Elafin in Vitro and in Vivo against Genital Herpes. Drannik, A.G., K. Nag, J.M. Sallenave, and K.L. Rosenthal. Journal of Virology, 2013. [Epub ahead of print]; PMID[23637403].
[PubMed] OV_0426-050913.
Citations from the ISI Web of Knowledge Listings for O.V.
12. N-Substituted benzyl matrinic acid Derivatives Inhibit Hepatitis C Virus (HCV) Replication through Down-regulating Host Heat-stress Cognate 70 (Hsc70) Expression. Du, N.N., Z.G. Peng, C.W. Bi, S. Tang, Y.H. Li, J.R. Li, Y.P. Zhu, J.P. Zhang, Y.X. Wang, J.D. Jiang, and D.Q. Song. Plos One, 2013. 8(3); ISI[000316407400047].
[WOS] OV_0426-050913.
13. Design of Histidine-rich Peptides with Enhanced Bioavailability and Inhibitory Activity against Hepatitis C Virus. Hong, W., R.H. Zhang, Z.Y. Di, Y.W. He, Z.H. Zhao, J. Hu, Y.L. Wu, W.X. Li, and Z.J. Cao. Biomaterials, 2013. 34(13): p. 3511-3522; ISI[000316770100035].
[WOS] OV_0426-050913.
14. Design, Synthesis and Antiviral Activity of 2-(3-Amino-4-piperazinylphenyl)chromone Derivatives. Kim, M.K., H. Yoon, D.L. Barnard, and Y. Chong. Chemical & Pharmaceutical Bulletin, 2013. 61(4): p. 486-488; ISI[000316831300018].
[WOS] OV_0426-050913.
15. Anti-Hepatitis B Virus Lignans from the Root of Streblus asper. Li, J., A.P. Meng, X.L. Guan, J. Li, Q. Wu, S.P. Deng, X.J. Su, and R.Y. Yang. Bioorganic & Medicinal Chemistry Letters, 2013. 23(7): p. 2238-2244; ISI[000316642900066].
[WOS] OV_0426-050913.
16. Discovery of Novel Tricyclic Indole Derived Inhibitors of HCV NS5B RNA Dependent RNA Polymerase. Venkatraman, S., F. Velazquez, S. Gavalas, W.L. Wu, K.X. Chen, A.G. Nair, F. Bennett, Y.H. Huang, P. Pinto, Y.H. Jiang, O. Selyutin, B. Vibulbhan, Q.B. Zeng, C. Lesburg, J. Duca, H.C. Huang, S. Agrawal, C.K. Jiang, E. Ferrari, C. Li, J. Kozlowski, S. Rosenblum, N.Y. Shih, and F.G. Njoroge. Bioorganic & Medicinal Chemistry, 2013. 21(7): p. 2007-2017; ISI[000316770300043].
[WOS] OV_0426-050913.